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Background: Primary nephrotic syndrome (NS) is a common disease in children. Lipid nephrotoxicity and cellular
immune dysfunction are known features of this disease. Recently, CXCL16 was found to participate in inflammation
and mediate cellular uptake of lipids. Here, we investigated the involvement of CXCL16 in the occurrence and
development of primary NS.
Methods: Serum CXCL16, blood lipids and albumin, 24-hour urine protein, interferon-γ and immune cells were
detected in 25 children with steroid sensitive NS during their active nephrotic and remissive stages. Twenty healthy
children served as the control group.
Results: Levels of serum CXCL16, blood lipids, interferon-γ and CXCR6+ T cells were significantly increased and
albumin and NK cell number were significantly decreased in the active status group compared with remissive status
and control groups. Correlation analysis showed that serum CXCL16 was positively correlated with blood lipids,
24-hour urine protein, interferon-γ and CXCR6+ T cells but negatively correlated with albumin in patients with
active NS.
Conclusion: Serum CXCL16 was increased in patients with active NS and correlated with blood lipids, urine protein
and immune and inflammation responses, suggesting that CXCL16 may serve as a useful index or biomarker for
disease activity in children with nephrotic syndrome.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1120468411154766.
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Nephrotic syndrome (NS) is a nonspecific disorder of
the kidney stemming either directly from kidney disease
(primary NS) or indirectly via conditions in other parts
of the body affecting the kidney (secondary NS) [1,2].
NS is characterized primarily by high proteinuria (>3 g/dL),
hypoalbuminemia and edema resulting from damage to the
glomerular filtration membrane, causing the kidney to
leak large amounts of plasma protein from the blood
into the urine. This trait is typically accompanied by* Correspondence: zhen6576@126.com
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stated.dyslipidemia with elevated plasma cholesterol and tri-
glycerides. In vitro studies have demonstrated that the
major components of lipids, such as low-density lipopro-
tein (LDL), oxidized LDL (oxLDL) and very low-density
lipoprotein, could directly stimulate mesangial cells to
proliferate and secrete inflammatory factors, including
IL-6, TGF-β, MCF-1, connective tissue growth factor and
PDGF. In addition, LDL and oxLDL could promote the
activation of renal immune cells, subsequently upre-
gulating NF-κB activity and hastening the release of
inflammatory factors [3]. Therefore, kidney inflammation
may be the result of a hyperlipidemia-induced influx of
inflammatory mediators. However, the mechanism of
lipid deposition in the kidney, the initial step for the
development of primary NS, is largely unknown.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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involved in inflammation and the immune response. The
chemokine superfamily consists of nearly 50 chemokines
and 20 chemokine receptors [4], and the interaction of
chemokines and their receptors is a key mediator of in-
flammation and arteriosclerosis. C-X-C motif chemokine
ligand 16 (CXCL16), first described by Matloubian [5]
and Wilbanks [6], exists in transmembrane-bound and
soluble forms. Transmembrane-bound CXCL16 acts as
both a cell surface adhesion molecule and a novel scavenger
receptor. Furthermore, transmembrane-bound CXCL16
may be released to its soluble form upon digestion by a
disintegrin and metalloproteinase (ADAM) protein, specif-
ically ADAM10 and ADAM17. Soluble CXCL16 can
recruit activated immune cells that express CXCR6,
the receptor of CXCL16 [7-9], and mediate immune
response-related inflammation [10-12]. In recent years,
CXCL16 was found to participate in the development
of atherosclerosis. The major pathological feature of
atherosclerosis is the formation of foam cells, derived
from either macrophages or smooth muscle cells, and
CXCL16 is expressed on the surface of macrophages,
arterial smooth muscle cells and vascular endothelial
cells. Transmembrane-bound CXCL16 can also combine
with oxLDL and mediate the cellular uptake of lipids.
Thus CXCL16 may be involved in the formation of foam
cells. Taken together, the results of these studies imply
that CXCL16 may, through the mediation of both lipid
deposition and immune and inflammatory responses,
be involved in the development of primary NS. However,
the degree to which CXCL16 participates in the occur-
rence of primary NS in children is largely unknown.
This study aims to reveal the function of CXCL16 in
the occurrence of childhood primary NS by monitoring
levels of CXCL16 protein in the serum of children with
primary NS and assessing any correlation with interferon-
γ (IFN-γ), 24-hour urine protein, serum albumin and lipid
metabolism. Through the data, we hope to establish a new
theoretical basis by which to improve understanding and
treatment of this disease.
Materials and methods
Subjects
Of 50 children with primary nephrotic syndrome admitted
in our department from January 2010 to June 2011, 25
with complete data and off steroid treatment were
retrospectively enrolled in this study. This group con-
sisted of 16 males and nine females ranging in age from
1.5 to 13 years (median = 5.0 years).
Patients were tested during both active and remissive
stages over the course of at least three months. Twenty
age-matched healthy children from a local school or
kindergarten were chosen as the healthy controls. This
group consisted of 12 males and eight females ranging inage from 3 to 12 years (median = 6.5 years). We confirmed
that these children were without current or past kidney
disease, infectious disease or kidney-related family history.
At the time of testing, no patient or control was taking
any immunomodulating drug (e.g., cyclosporine A, cyclo-
phosphamide, levamisole or MMF) which could affect the
immunologic parameters studied.
There was no significant difference in age or gender
between the NS groups and control group (P > 0.05). This
study was approved by the ethics committee of Provincial
Hospital Affiliated to Shandong University, and written
informed consent for participation was obtained from
the parents of those who participated.
Definitions
Primary NS was defined by heavy proteinuria (urinary
protein > 50 mg/kg/day), hypoalbuminemia [serum al-
bumin < 2.5 g/dL] and hypercholesterolemia (serum
cholesterol > 5.72 mmol/L), with or without edema. Initial
treatment was comprised of 2 mg/kg/day (maximum
60 mg/day) of prednisone given orally in three divided
doses for four weeks followed by therapy on alternate
days for another four weeks. The daily dose was then
tapered down for 4–7 months and finally stopped.
The active stage of NS was defined as increased urin-
ary protein excretion (Albustix > 2+ for at least three
consecutive days or > 50 mg/kg/day) and serum albumin
concentration of < 25 g/L. Remission was defined as serum
albumin concentration of > 35 g/L and normal protein
excretion (Albustix trace or negative for at least three
consecutive days). “Steroid-sensitive” was defined as dis-
appearance of proteinuria (negative for three consecutive
days) following four weeks of prednisone treatment.
Patients who still had proteinuria were considered to
be steroid resistant.
Measurement of blood lipids, albumin and urine protein
Fasting levels of venous blood from each experimental
group were collected, and blood lipids were analyzed.
Serum albumin was measured using a bromocresol green
assay, and total cholesterol, LDL cholesterol, triglyceride
and 24-hour urine protein were measured on an AU5400
automatic biochemical analyzer using a colorimetric assay.
Enzyme-linked immunosorbent assays (ELISAs)
Sandwich ELISA was used to detect serum CXCL16,
IFN-γ and oxLDL levels according to the manufacturer’s
instructions. Briefly, standard proteins and samples were
diluted with standard diluent buffer, and 100 μl of stan-
dards, controls and diluted samples was added to the
appropriate microtiter wells. The wells were covered and
incubated for two hours at room temperature. Biotin-
conjugated detection antibody (100 μl) (Life Technologies,
CA, USA) was added into each well after washing with
Figure 1 Serum CXCL16 increased in active nephrotic
syndrome. p < 0.05(△) vs Control; p < 0.05(★) vs Remissive NS.
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temperature followed by another PBS wash step. Anti-
rabbit IgG-HRP (100 μl) was then added to each well,
and then the wells were covered and allowed to incubate
for another 30 minutes at room temperature. Following
another wash step, stabilized chromogen (100 μl) was
added to each well, and incubation was continued for 30
minutes at room temperature in the dark. Lastly, stop
solution was added to each well, and the absorbance of
each well at 450 nm was recorded by a microtiter plate
reader. A smooth standard curve was drawn according
to standard protein OD values. Unknown sample protein
concentrations were derived from this standard curve.
Isolation of mononuclear cells from peripheral blood
Peripheral blood was diluted with PBS and then gently
layered on top of Ficoll-Paque Plus solution (GE Health-
care Biosciences, PA, USA) followed by centrifugation for
30 minutes at 1,600 rpm at room temperature. Peripheral
blood mononuclear cells (PBMCs) were collected from
the interface between the Ficoll-Paque layer and the
diluted plasma layer and transferred into a new tube,
centrifuged and washed twice with PBS. The cells were
then resuspended in PBS and separated into aliquots
for further analysis.
Detection of the T cell subpopulation and NK cells with
flow cytometry
Viable mononuclear cells (1 × 106) were suspended in
400 μl of cold FACS solution per sample. Prediluted
antibody mixture (100 μl) (BD company, NJ, USA) was
added to all samples and mixed by pipetting. After
incubating on ice for 45 minutes, the stained cells were
centrifuged and resuspended in 150 μl of FACS fix
solution prior to flow cytometric detection.
Statistical analysis
GraphPad Prism software (version 5) was used for data
analysis. Measurement data was described as mean ±
standard deviation. One-way analysis of variance was
used to compare means among three groups, while the
Newman-Keuls test was used to compare means between
any two groups. The Spearman’s two-tail test was used for
correlation analysis. Significance was set at P < 0.05.
Results
Serum CXCL16 increased in active nephrotic syndrome
We detected an increase in the levels of serum CXCL16 in
patients with active NS relative to those with remissive NS
and the control group. As shown in Figure 1, serum
CXCL16 in patients with active NS was calculated to be
0.40 ± 0.08 ng/ml, significantly higher than that of remis-
sive NS patients (0.35 ± 0.05 ng/ml) and the control group(0.34 ± 0.05 ng/ml) ( P < 0.05). These results suggested that
serum CXCL16 is increased in patients with active NS.
Serum CXCL16 is positively correlated with the
concentration of blood lipids in active NS patients
Hyperlipidemia is an important pathophysiological char-
acteristic of children with primary NS. We therefore
assessed the correlation between serum CXCL16 and
the concentration of blood lipids. The results shown in
Table 1 suggested that the concentration of blood total
cholesterol (CHOL), triglycerides (TG), low-density lipo-
protein cholesterol (LDL-C) and oxLDL in the active NS
group is significantly higher than that in the remissive NS
and control groups (P < 0.01). There was no statistically
significant difference in the concentration of blood lipids
between the remissive NS and control groups, consistent
with previous research. Correlation analysis revealed that
serum CXCL16 is positively correlated with CHOL, TG,
LDL-C and oxLDL, having correlation coefficients (r) of
0.796, 0.646, 0.725 and 0.740, respectively, in the active
NS group (P < 0.01). These results suggested that serum
CXCL16 is positively correlated with the concentration of
blood lipids in active NS patients.
Serum CXCL16 is positively correlated with 24-hour urine
protein but negatively correlated with albumin in active
NS patients
Leakage of protein from the blood into the urine is the
major characterizing disorder of NS. We therefore assessed
the correlation between serum CXCL16 and 24-hour
urine protein and albumin. The results shown in Table 1
demonstrated that 24-hour urine protein in the active
NS group was positive, with a value of 3.27 ± 1.12 g, and
24-hour urine protein in the remissive NS and control
groups was negative. Albumin in the active NS group
was significantly lower than that in the remissive NS
and control groups (P < 0.01). There was no significant
difference in 24-hour urine protein or albumin between
the remissive NS and control groups (P > 0.05), consistent
with previous research. Correlation analysis showed
that 24-hour urine protein was positively correlated with
CHOL, TG, LDL-C and oxLDL in active NS patients,
having correlation coefficients of 0.514, 0.631, 0.516 and
Table 1 Blood lipid, albumin and 24-hour urine protein measurement (mean ± SD)
Active NS Remissive NS Control
CXCL16 0.40 ± 0.08★△ 0.35 ± 0.06 0.34 ± 0.05
CHOL (mmol/L) 10.65 ± 3.99★★△△ 4.74 ± 1.31 3.90 ± 0.82
TG (mmol/L) 3.06 ± 1.15★★△△ 1.23 ± 0.52 1.01 ± 0.40
LDL-C (mmol/L) 7.61 ± 2.91★★△△ 3.01 ± 0.85 2.53 ± 0.66
oxLDL (μg/dL) 16.80 ± 2.30★★△△ 13.88 ± 2.95 12.15 ± 1.44
Albumin (μg/dL) 17.31 ± 5.21★★△△ 43.00 ± 2.49 44.08 ± 1.06
24-hour urine protein (g/24 h) 3.27 ± 1.12 —— ——
p < 0.05(△), p < 0.01(△△) vs Control; p < 0.05(★), p < 0.01(★★) vs Remissive NS.
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correlated with 24-hour urine protein but negatively corre-
lated with albumin in active NS patients, having correlation
coefficients of 0.736 and −0.628, respectively (P < 0.01).
Serum CXCL16 is positively correlated with IFN-γ in active
NS patients
Inflammation characterized by elevated inflammatory
cytokines is common in NS. We therefore detected the
pro-inflammatory protein IFN-γ in serum. As shown in
Figure 2A, IFN-γ was significantly higher in the active
NS group (90.12 ± 35.91 pg/ml) than in the remissive NS
group (61.00 ± 30.97 pg/ml) and control group (61.00 ±
34.19 pg/ml) (P < 0.05). Correlation analysis revealed
serum IFN-γ to be highly correlated with CHOL, TG,
LDL-C, oxLDL, 24-hour urine protein and albumin in
active NS patients, having correlation coefficients of
0.806, 0.767, 0.783, 0.825, 0.739 and −0.683, respectively
(P < 0.01). Serum IFN-γ was also positively correlated
with CXCL16 in active NS patients, having a correlation
coefficient of 0.681 (P < 0.01, Figure 2B).
Serum CXCL16 is positively correlated with CXCR6+ T
cells in active NS patients
IFN-γ is a proinflammatory cytokine produced by T cells
and natural killer (NK) cells. We therefore detectedFigure 2 Serum CXCL16 is positively correlated with IFN-γ in active N
analysis between serum CXCL16 and IFN-γ in active NS patients. p < 0.05(△)alterations in the T cell subpopulation and NK cells in
active NS patients. The results showed that the percentage
of CD3+ T cells and CD4+ T cells in the active NS
group (59.31 ± 5.02% and 26.52 ± 2.62%, respectively) was
significantly decreased compared with the control group
(68.85 ± 4.09% and 35.63 ± 3.74%, respectively) (P < 0.01).
The percentage of CD3+ T cells and CD4+ T cells in the
remissive NS group was 71.90 ± 4.75% and 37.57 ± 3.76%,
respectively, but there was no statistically significant differ-
ence when compared with the control group (P > 0.05,
Figure 3A and 3B). The percentage of CD8+ T cells in
the active NS group (28.35 ± 3.90%) and the remissive
NS group (28.17 ± 2.77%) was higher than that in the
control group (25.67 ± 2.66%) (P < 0.05, Figure 3C). We
also detected the percentage of CXCL16+ T cells in each
group, and the results showed that CXCL16+ T cells
were significantly increased in the active NS group
(9.36 ± 2.22%) compared with the remissive NS group
(5.10 ± 1.53%) and control group (4.39 ± 1.76%) (P < 0.01,
Figure 3D). Correlation analysis showed that serum
CXCL16 was highly correlated with the number of
CXCR6+ T cells (r = 0.681, P < 0.01, Figure 3E). To our
surprise, the percentage of NK cells in the active NS group
(5.68 ± 1.69%) and the remissive NS group (11.15 ± 3.66%)
was significantly decreased compared with the control
group (17.74 ± 5.91%) (P < 0.01, Figure 3F).S patients. (A) Serum IFN-γ level in different groups. (B) Correlation
vs Control; p < 0.05(★) vs Remissive NS.
Figure 3 Serum CXCL16 is positively correlated with CXCR6+ T cells in active NS patients. (A) The percentage of CD3+ T cells in different
groups. (B) The percentage of CD4+ T cells in different groups. (C) The percentage of CD8+ T cells in different groups. (D) The percentage of
CXCR6+ T cells in different groups. (E) Correlation analysis between serum CXCL16 and CXCR6+ T cells in active NS patients. (F) The percentage
of NK cells in different groups. p < 0.05(△), p < 0.01(△△) vs Control; p < 0.05(★), p < 0.01(★★) vs Remissive NS.
Zhen et al. Diagnostic Pathology 2014, 9:23 Page 5 of 8
http://www.diagnosticpathology.org/content/9/1/23Discussion
Hyperlipidemia is an important pathophysiological change
in children with primary NS. In 1982, Moorhead et al.
proposed the theory of lipid nephrotoxicity resulting
from abnormalities of lipid metabolism in chronic kidney
disease [3]. The results of many clinical and animal
models strongly support this hypothesis [13-16]. Lee
et al. found foam cells, lipid deposits and oxLDL in
renal biopsies of focal segmental glomerulosclerosis
(FSGS) [17]. Proteinuria and FSGS in rats with puromycin
nephropathy were shown to worsen with cholesterol
intake [18], and Joles et al. found that podocytes were
an early target of kidney injury in animals on a high-fat
diet [19]. Therefore, hyperlipidemia and lipid depos-
ition in the kidney are very important risk factors for
glomerulosclerosis.This study indicates that the levels of blood total chol-
esterol, triglycerides, LDL-C and oxLDL in the active
NS group were significantly higher than those in the
remissive NS and normal control groups, implying
metabolic disorder of blood lipids during NS activity.
Lipids can stimulate interactions between mesangial
cells and monocytes and induce monocytes to secrete
large amounts of inflammatory cytokines, such as IL-
6, PDGF-1 and TGFβ1 [3]. The IL-1β has been shown
to induce the expression of scavenger receptors, in-
crease cholesterol levels in vascular smooth muscle cells,
mesangial cells and macrophages, interfere with feedback
regulation of LDL receptors leading to continuous uptake
of LDL, and promote the formation of foam cells [20,21].
oxLDL is a major contributor to foam cell formation and
may also cause injury to endothelial cells and promote
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the development of atherosclerosis. oxLDL is a powerful
chemokine of macrophages and T lymphocytes that can
recruit circulating monocytes through direct or indirect
induction of chemokine and adhesion molecule production
in smooth muscle cells, mesangial cells and/or endothelial
cells [22,23]. In addition, in vitro assays identified certain
cytotoxic side effects of oxLDL, including apoptosis of
podocytes [23]. In this study, correlation analysis showed
that levels of blood total cholesterol, triglycerides, LDL-C
and oxLDL were positively correlated with 24-hour
urine protein in the active NS group, suggesting that
dyslipidemia may be involved in the occurrence of NS.
However, reports of the participation of oxLDL in the
occurrence of primary NS in children are rare.
In this study, we showed a significant increase in the
levels of serum IFN-γ in children with active simple-type
NS relative to the remissive NS and normal control groups.
Furthermore, serum IFN-γ in the active NS group was
positively correlated with 24-hour urine protein and
negatively correlated with plasma albumin. These results
indicate that IFN-γ may be involved in the pathogenesis of
idiopathic NS and associated with NS activity. Notably,
serum IFN-γ in children with active NS was also positively
correlated with levels of blood total cholesterol, tri-
glycerides, LDL-C and oxLDL, indicating that IFN-γ
may be involved in NS dyslipidemia and promote lesion
inflammation.
Reports of CXCL16 in the development of inflammation
in kidney disease are few. While screening for potential
biomarkers of lupus nephritis, Tianfu Wu et al. [16]
discovered CXCL16 protein in the urine of mice with
spontaneous lupus nephritis. Notably, the presence of
CXCL16 correlated with the period of disease activity.
In addition, increased CXCL16 was found in the urine
of patients with lupus nephritis and was significantly
associated with urinary protein levels as well as activity
index and score of systemic lupus erythematosus. Xia
Y et al. [24] found that CXCL16 knockout mice were
protected from angiotensin II-induced renal dysfunction,
proteinuria, and fibrosis, and proved that CXCL16 plays
a pivotal role in the pathogenesis of hypertensive kidney
injury and fibrosis through regulation of macrophage
and T cell infiltration and bone marrow-derived fibro-
blast accumulation. However, few studies have focused
on the association of CXCL16 alteration in children
with primary NS.
Schramme et al. not only found that CXCL16 was
expressed in human mesangial cells (hMCs), but also
confirmed that a mixture of cytokines (IFN-γ, TNF-α
and IL-1β) could further increase the expression of
CXCL16 [25]. Through the stimulation of cultured human
podocytes in vitro using IFN-γ, TNF-α and angiotensin II,
Gutwein et al. found that IFN-γ and TNF-α could increasethe expression of podocyte transmembrane and soluble
CXCL16, while angiotensin II stimulation had no effect on
CXCL16 expression [26]. Wagsater et al. investigated the
effect of IFN-γ, TNF-α, IL-12 and other cytokines on the
expression of CXCL16 [10]. Their results indicated that
IFN-γ was the strongest stimulating factor for CXCL16
expression, up-regulating levels of CXCL16 mRNA as well
as transmembrane and soluble forms of the protein. Our
study showed that both serum CXCL16 and IFN-γ in
the active NS group were significantly increased. Further-
more, correlation analysis revealed a positive correlation
between levels of serum CXCL16 and IFN-γ, suggesting
that increased IFN-γ in active simple-type NS may be a
stimulus for elevated serum CXCL16. However, the exact
mechanism of this activity requires further study.
Shalhoub showed that circulating lymphatic factors could
result in damage to the glomerular basement membrane
and thereby proposed that NS might be associated with
T-cell immune abnormalities [27]. Schramme et al. found
that acute tubular injury was associated with increased
CXCL16 in renal transplant urine and related to increased
CXCL16 in the distal tubule and collecting duct [28].
Currently, CXCR6 is the only known receptor of CXCL16.
CXCR6 is primarily expressed in naive CD8+ T cells,
activated CD4+ T cells, activated CD8+ T cells, NK cells
and polymorphonuclear neutrophils [6,29]. Chemotaxis
assays indicated that only cells with high expression of
CXCR6 could respond to CXCL16 [30]. Using a rat
nephritis model with anti-glomerular basement membrane
antibody, Garcia et al. found that CXCL16 was expressed
in glomerular endothelial cells and regulated macrophage
adhesion [13]. During acute inflammation, blockage of
CXCL16 significantly inhibited monocyte/macrophage
infiltration and reduced glomerular damage and protein-
uria; therefore, CXCL16 and CXCR6 may play an important
role in the migration of T cells [5]. It is suggested that
T cell migration into inflammatory lesions is mediated
by the specific interaction of CXCL16 and CXCR6. Previ-
ous studies confirmed that CXCR6 and secreted soluble
CXCL16 might be responsible for inducing chemotactic
migration of proinflammatory cells into arthritic joints
and sites of liver inflammation [31-34]. However, there
are few reports regarding CXCR6 induction of chemo-
tactic migration of inflammatory cells in renal lesions
of childhood NS.
Our results showed that the ratio of peripheral blood
CD3+, CD4+, CD4+ 8+ and NK (CD16+ 56+) T cells was
significantly lower in the active NS group than in the
remissive NS and normal control groups. Furthermore,
active NS group CD8+ T cells were significantly higher
in number than in the control group, suggesting that the
ratio between T lymphocyte subsets was unbalanced
during primary NS activity, consistent with the reported
literature. However, CD8+ T cells were still more numerous
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and NK (CD 16+ 56+) T cells in the remissive group were
fewer in number than in the control group. Peripheral
blood CXCR6+ T cell numbers in the active NS group were
significantly higher than in the remissive NS and normal
control groups, while peripheral blood CXCR6+ T cell
numbers in the remissive NS group were no different
than the normal control group. Moreover, correlation
analysis revealed that the levels of serum CXCL16 in
the active NS group were positively correlation with the
quantity of peripheral blood CXCR6+ T cells, suggesting
that CXCR6 and soluble CXCL16 may participate together
in the occurrence of NS. Further study is needed to
confirm the level of involvement of CXCL16 and CXCR6
in the migration of inflammatory cells to renal lesions.
In summary, we found that serum CXCL16 is increased
in patients with active NS and is correlated with blood
lipids, 24-hour urine protein and immune and inflamma-
tion responses, suggesting that CXCL16 may serve as a
useful index or biomarker for disease activity in children
with nephrotic syndrome.
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